PriceTargets.com logo

SAB Biotherapeutics - SABS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.40
  • Forecasted Upside: 166.67%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$4.65 As of 12/20/2024 06:31 PM ET
▲ +0.75 (19.23%)

This chart shows the closing price for SABS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New SAB Biotherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SABS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SABS

Analyst Price Target is $12.40
▲ +166.67% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for SAB Biotherapeutics in the last 3 months. The average price target is $12.40, with a high forecast of $25.00 and a low forecast of $6.00. The average price target represents a 166.67% upside from the last price of $4.65.

This chart shows the closing price for SABS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in SAB Biotherapeutics. This rating has held steady since September 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/7/2024Chardan CapitalReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
10/9/2024Craig HallumInitiated CoverageBuy$11.00
9/12/2024OppenheimerReiterated RatingOutperform ➝ Outperform$12.00 ➝ $12.00
9/9/2024Chardan CapitalReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
8/28/2024OppenheimerInitiated CoverageOutperform$12.00
8/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
8/12/2024Chardan CapitalReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
6/7/2024Brookline Capital ManagementInitiated CoverageBuy$8.00
5/21/2024Chardan CapitalReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
5/21/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00
4/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00
4/16/2024Chardan CapitalReiterated RatingBuy ➝ Buy$25.00
4/2/2024Chardan CapitalBoost TargetBuy ➝ Buy$3.00 ➝ $25.00
4/2/2024HC WainwrightLower TargetBuy ➝ Buy$10.00 ➝ $6.00
1/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$1.00 ➝ $10.00
11/14/2023HC WainwrightLower TargetBuy ➝ Buy$2.00 ➝ $1.00
10/5/2023LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral
8/21/2023HC WainwrightLower TargetBuy ➝ Buy$4.00 ➝ $2.00
4/13/2023HC WainwrightReiterated RatingBuy$4.00
4/3/2023HC WainwrightReiterated RatingBuy$4.00
11/29/2022HC WainwrightInitiated CoverageBuy$4.00
8/11/2022Chardan CapitalLower TargetBuy$7.00 ➝ $3.00
8/11/2022Robert W. BairdLower Target$8.00 ➝ $4.00
5/13/2022Chardan CapitalLower Target$10.00 ➝ $7.00
4/1/2022Chardan CapitalLower TargetBuy$17.00 ➝ $10.00
12/2/2021Northland SecuritiesBoost TargetOutperform$18.00 ➝ $21.00
11/25/2021Robert W. BairdReiterated RatingBuy$23.00
11/5/2021Chardan CapitalInitiated CoverageBuy$17.00
11/1/2021Robert W. BairdInitiated CoverageOutperform$23.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
SAB Biotherapeutics logo
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
Read More

Today's Range

Now: $4.65
Low: $3.85
High: $4.70

50 Day Range

MA: $3.30
Low: $2.42
High: $4.65

52 Week Range

Now: $4.65
Low: $2.16
High: $7.70

Volume

115,398 shs

Average Volume

36,660 shs

Market Capitalization

$42.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59

Frequently Asked Questions

What sell-side analysts currently cover shares of SAB Biotherapeutics?

The following equities research analysts have issued research reports on SAB Biotherapeutics in the last twelve months: Brookline Capital Management, Chardan Capital, Craig Hallum, HC Wainwright, and Oppenheimer Holdings Inc..
View the latest analyst ratings for SABS.

What is the current price target for SAB Biotherapeutics?

0 Wall Street analysts have set twelve-month price targets for SAB Biotherapeutics in the last year. Their average twelve-month price target is $12.40, suggesting a possible upside of 166.7%. Chardan Capital has the highest price target set, predicting SABS will reach $25.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $6.00 for SAB Biotherapeutics in the next year.
View the latest price targets for SABS.

What is the current consensus analyst rating for SAB Biotherapeutics?

SAB Biotherapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SABS will outperform the market and that investors should add to their positions of SAB Biotherapeutics.
View the latest ratings for SABS.

What other companies compete with SAB Biotherapeutics?

Other companies that are similar to SAB Biotherapeutics include Achieve Life Sciences, Regulus Therapeutics, Agenus, Fortress Biotech and Curis. Learn More about companies similar to SAB Biotherapeutics.

How do I contact SAB Biotherapeutics' investor relations team?

SAB Biotherapeutics' physical mailing address is 300 W. 41ST STREET SUITE 202, MIAMI BEACH FL, 33140. The company's listed phone number is 605-679-6980 and its investor relations email address is [email protected]. The official website for SAB Biotherapeutics is www.bigcypressaccorp.com. Learn More about contacing SAB Biotherapeutics investor relations.